Dr John Campbell had done a video on this- It looks as if there is a connection- that is of yet to be discovered (What is the mechanism for this outcome)
I found a study from the NIH from March of this year
Keep in mind the entire study is available at the link above, and limited excerpts are below. That said there seems to be a connection, which is very unfortunate for those who now have MS because of the jab
Methods: In this longitudinal observational case-control study, a total of 65 participants were studied, who were divided into two groups. Group A included 32 MS patients who were diagnosed post-COVID-19 vaccine administration and group B included 33 participants who received COVID-19 vaccines and did not develop MS.
Group B was used as a control. The Chi-square test and logistic regression analysis were carried out using Statistical Product and Service Solutions (SPSS) (IBM SPSS Statistics for Windows, Armonk, NY) software.
Results: Univariate and multivariate logistic regression analysis was performed and a significant correlation between the risk factors and the development of MS post-COVID-19 vaccination was identified.
Conclusion: The risk factors, identified in this study, can be used as significant independent predictors for developing MS post-COVID-19 vaccinations.
Because vaccines are and have been a one size fits all intervention, which is ridiculous for the simple and very obvious reason we are not all the same- therefore one size cannot fit all. That’s a huge problem with all jabs.
A wide variety of inflammatory diseases has been associated with the administration of various vaccines. Concerns that demyelinating diseases of the central nervous system (CNS) might trigger after vaccine administration have existed for a long time .
. Vaccines against the influenza viruses have been widely reported as vaccinations associated with CNS demyelinating diseases. Moreover, other vaccines such as human papillomavirus (HPV), hepatitis A or B, rabies, measles, rubella, yellow fever, anthrax, meningococcus, and tetanus have also been reported as a trigger for post-vaccination CNS demyelinating diseases .
CNS demyelination diseases such as acute disseminated encephalomyelitis (ADEM) and neuromyelitis optica spectrum disorders (NMOSD) were reported by different health organizations following the administration of all types of approved COVID-19 vaccines. However, only a few patients were newly diagnosed with MS following vaccine administration .
This study aimed to illustrate the prevalence of new-onset MS post-COVID-19 vaccination and correlate it with its possible predictors in a multi-center case-control study.
Onset of MS and vaccine type
The time of onset of these symptoms post-COVID-19 vaccinations ranged between one and two months with a median time of two months. Among case-control groups, 12 have received the Pfizer vaccine, six have received the Moderna vaccine, and 15 have received the AstraZeneca vaccine. Among MS, 20 have received the Pfizer vaccine, three have received the Moderna vaccine, and nine have received the AstraZeneca vaccine. The presentation of symptoms among the MS group appeared after the first dose of vaccine in 25 patients, while it appeared after the second dose of vaccine in seven patients (Table (Table11).
In this study, it is proposed that the COVID vaccine can trigger the immune system which helps with self-antigens production of CNS in susceptible people. Also, this study showed that there were significant correlations between the following risk factors and developing MS post-COVID-19 vaccinations: Pfizer vaccine, low serum level of vitamin D, positive EBNA1-IgG, and family history of MS. These risk factors can be used as significant independent predictors for developing MS post-COVID-19 vaccinations. However, genetic and environmental factors cannot be ruled out. Furthermore, in this study, a definite association between COVID-19 vaccine with MS is not described, rather it is aimed to highlight the possibility of this association as an independent risk factor that can trigger new onset MS in the susceptible group. Though, more data is needed for further correlation.